830 Winter St
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
420 articles with ImmunoGen Inc.
ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress
ImmunoGen Inc, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine
ImmunoGen, Inc. today announced that Company will host a conference call at 8:00a.m. on Friday, Nov 2, 2018.
ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO
ImmunoGen, Inc. today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany.
9/25/2018Ovarian cancer is the fifth leading cause of cancer-related deaths in the United States. It is estimated that this year there will be more than 22,000 women in the U.S. diagnosed with the disease and about 14,000 disease-related deaths.
ImmunoGen, Inc. today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
9/10/2018Let's take a look at who made a splash in the pharma and biotech world the past week.
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—...
AIT Bioscience, LLC Chief Executive Officer, Terri Pascarelli has been named among the 2018 PharmaVOICE 100 honorees.
Mirvetuximab Soravtansine Granted Fast Track Designation by FDA
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer
The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than three prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy.
ImmunoGen Inc., Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $11.00 per share.
ImmunoGen, Inc. today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price of $11.00 per share.
ImmunoGen, Inc. announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common stock in an underwritten public offering.
ImmunoGen, Inc. announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference.
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
ImmunoGen, Inc. reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.
ImmunoGen, Inc. announced that the Company will present at the upcoming Deutsche Bank 43rd Annual Health Care Conference.
ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
ImmunoGen, Inc. announced that the FORWARD I Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer will continue as planned without modification.
ImmunoGen, Inc. is a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer
ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading.